Every week we have a “newsletter” which gets emailed to CARES staff and board members. Its purpose is to highlight recent HIV-related news from the United States as well as other countries. A short informational teaser lets everyone know what each news item is about and a link is included at the end for those who have an interest in reading the story in its entirety. We pull information from various news, government and health-related websites, as well as personal blogs. From time to time we include links to webinars that might be useful in the work that we do.
Here is this week’s update:
Webinar: Significance of the Affordable Care Act in African American Communities
The Black AIDS Institute and Harvard University Center For AIDS Research will present a free webinar on Wednesday, September 18th from 1:00—2:30 p.m. Eastern time.
The webinar is free and open to anyone who is interested in participating.
Attendees will learn about the Affordable Care Act, including Medicaid expansion and insurance marketplaces, as well as the Ryan White HIV/AIDS program.
To register online, click on this link: http://fs3.formsite.com/divofaids/ACA09182013/index.html
Why Mosquitoes Can’t Transmit HIV
Mosquitoes can not transmit HIV. We all know this, but do we know why?
Joe Conlon, former Navy entomologist and current technical advisor for the American Mosquito Control Association, told businessoutsider.com that first of all, when a mosquito bites you, it draws your blood into its gut where acids kill the virus.
Mosquitoes use two different tubes to suck up blood and to inject you with saliva that stops your blood from clotting up while it’s drinking.
“For a mosquito to transmit a disease, it’s gotta pick up the virus. The virus has to survive in the gut and then get outside the gut into the body cavity and then eventually into the salivary glands to be injected into something else. It’s a very complicated process, and with HIV, it just doesn’t happen,” Conlon said.
FDA Approves Tivicay To Treat HIV
The FDA has approved GlaxoSmithKline’s drug Tivicay to treat the most common strain of HIV. The once-daily drug (generic name dolutegravir) belongs to a class of integrase inhibitors that block the virus from entering cells.
Tivicay is for use in combination with other antiretroviral drugs to treat infected adults who have been treated with other drugs or are new to treatment. The FDA also approved the drug for use in children aged 12 years and over, who weigh at least 88 lbs. and who have not received treatment with a similar drug.
Click the link to learn more: http://www.edgeonthenet.com/health_fitness/hiv_aids/148492/fda_approves_glaxosmithkline_aids_drug_tivicay